MARKET

ENGNW

ENGNW

Forbion European Acquisition Corp
NASDAQ
3.180
+1.070
+50.71%
Closed 15:45 02/06 EST
OPEN
2.280
PREV CLOSE
2.110
HIGH
3.290
LOW
2.280
VOLUME
94.69K
TURNOVER
--
52 WEEK HIGH
4.200
52 WEEK LOW
0.5100
MARKET CAP
--
P/E (TTM)
-1.3858
1D
5D
1M
3M
1Y
5Y
1D
enGene Holdings nimmt am Guggenheim Emerging Outlook: Biotech Summit teil
Reuters · 3d ago
enGene Holdings CEO to Join Guggenheim Emerging Outlook Biotech Summit
Reuters · 3d ago
ENGENE HOLDINGS INC <ENGN.O>: JEFFERIES INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $28
Reuters · 01/30 06:10
enGene: Two Major Catalysts On Deck For 2nd Half Of 2026
Seeking Alpha · 01/27 20:17
enGene Holdings Issues 2026 Warrants to Purchase Common Shares
Reuters · 01/21 21:07
ENGENE HOLDINGS - SECURES UP TO $100 MLN FOR DETALIMOGENE DEVELOPMENT & COMMERCIALIZATION FOR BLADDER CANCER
Reuters · 01/20 22:37
ENGENE ANNOUNCES EXPANDED $125 MILLION DEBT FACILITY WITH HERCULES CAPITAL, INC.
Reuters · 01/20 22:37
enGene Secures Expanded $125 Million Debt Facility from Hercules Capital
Reuters · 01/20 22:35
More
About ENGNW
enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Company’s proprietary dually derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, the Company’s DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract, and its lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium.

Webull offers enGene Holdings Inc stock information, including NASDAQ: ENGNW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENGNW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENGNW stock methods without spending real money on the virtual paper trading platform.